$5.38
-2.0%TriplePoint Venture Growth BDC Corp. is a business development company specializing investments in venture capital-backed companies at the growth stage investments. It also provides debt financing to venture growth space companies which includes growth capital loans, secured and customized loans, equipment financings, revolving loans and direct equity investments. The fund seeks to invest in e-commerce, entertainment, technology and life sciences sector. Within technology the areas of focus include: Security, wireless communication equipments, network system and software, business applications software, conferencing equipments/services .big data, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, software, software as a service, and other technology related subsectors and within life sciences the areas of focus include: biotechnology, bio fuels/bio mass, diagnostic testing and bioinformatics, drug delivery, drug discovery, healthcare information systems, healthcare services, medical, surgical and therapeutic devices, pharmaceuticals and other life science related subsectors. Within growth capital loans it invests between $5 million and $50 million, for equipment financings it invests between $5 million and $25 million, for revolving loans it invests between $1 million and $25 million, and for direct equity investments it may invest between $0.1 million and $5 million (generally not exceeding 5% of the company's total equity). The debt financing products are typically structured as lines of credit and it invests through warrants and secured loans. It targeted returns between 10% and 18%. It does not take board seat in the company.
Chief Compliance Officer
Chief Financial Officer
Co-Founder, Chairman & Chief Executive Officer
Co-Founder, President, Chief Investment Officer, Secretary, Treasurer & Director
During the last 12 months, insiders have purchased $25.94M worth of TPVG shares, with no selling activity reported.
0
0.00
0
0.00
+0
+$0
1.4M
9.13M
0
0.00
+9.1M
+$9.13M
1.5M
9.11M
0
0.00
+9.1M
+$9.11M
1.2M
7.70M
0
0.00
+7.7M
+$7.70M
Labe James
Director, Officer: Chief Executive Officer
$12.97M
Srivastava Sajal
Director, Officer: President And Cio
$12.97M
No selling activity
Strong bullish signal with $25.94M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero sellingโthe most bullish possible insider signal.
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
TPVG - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 07, 2025 | March 07, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 08, 2024 | March 08, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | March 08, 2023 | March 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | March 08, 2022 | March 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 09, 2021 | March 09, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 06, 2020 | April 06, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 14, 2019 | April 26, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | May 22, 2018 | June 21, 2018 | 2018 | |
DEF 14A DEF 14A 2018 N/A | March 14, 2018 | April 25, 2018 | 2018 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.